Volume 50, Issue 10 pp. 878-883
CASE STUDY

Mpox virus and coinfections: An approach to rapid diagnosis

Kristina M. Derrick MD, ScM

Corresponding Author

Kristina M. Derrick MD, ScM

Department of Dermatology, SUNY Downstate Health Sciences University, Brooklyn, New York, USA

Correspondence

Kristina M. Derrick, Department of Dermatology, SUNY Downstate Health Sciences University, Brooklyn, NY 11203, USA.

Email: [email protected]

Search for more papers by this author
Justin W. Marson MD

Justin W. Marson MD

Department of Dermatology, SUNY Downstate Health Sciences University, Brooklyn, New York, USA

Search for more papers by this author
Srita Chakka MD

Srita Chakka MD

Department of Dermatology, SUNY Downstate Health Sciences University, Brooklyn, New York, USA

Search for more papers by this author
Edward R. Heilman MD

Edward R. Heilman MD

Department of Dermatology, SUNY Downstate Health Sciences University, Brooklyn, New York, USA

Search for more papers by this author
First published: 09 July 2023
Citations: 1

Abstract

We report a case of a 42-year-old immunocompromised (human immunodeficiency virus [HIV], CD4 count 86 cells/μL) Black male who presented with fever, oropharyngeal candidiasis, and phimosis, followed by eruption of umbilicated papulovesicles most concentrated on the face. The patient was diagnosed with Mpox (MPXV, formerly monkeypox), herpes simplex virus 1 (HSV1), varicella-zoster virus (VZV), and late latent syphilis. Tzanck smear of a Mpox lesion proved a useful and rapidly obtained pertinent negative test, lacking the typical changes of HSV/VZV (multinucleation, margination, and molding). A biopsy specimen showed viral changes consistent with both Mpox (ballooning degeneration and multinucleated keratinocytes) and herpesvirus (multinucleated epithelial giant cell within a zone of follicular necrosis). Lesion PCR was positive for HSV1 and MPXV, and negative for HSV2 and VZV. Immunohistochemistry was positive for VZV and orthopoxvirus. Empiric treatment for HSV/VZV in patients with suspected or confirmed Mpox should be considered for patients with HIV or other immunocompromised patients. It is important to recognize that MPXV, HSV, and VZV may all be present and difficult to distinguish clinically. More than one test modality (PCR, H&E, immunohistochemistry, and Tzanck) and multiple lesion samples may be required to thoroughly evaluate widespread papulovesicular eruptions, especially in immunocompromised patients.

CONFLICT OF INTEREST STATEMENT

The authors declare no conflicts of interest.

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.